Zobrazeno 1 - 4
of 4
pro vyhledávání: '"O. A. Smrkovski"'
Autor:
K. B. Reeds, Heather Wilson-Robles, Jessica Lawrence, Z. M. Wright, C. Saba, Michael O. Childress, S. Gillings, Nikolaos G. Dervisis, Timothy J. Stein, K. R. Vickery, Kristine Burgess, S. Rau, Stephanie E. Schleis, C. J. DeRegis, B. Brugmann, Christine M. Budke, Travis Laver, O. A. Smrkovski, M. Silver, A. Novosad, Janet Lori, G. S. Post, Tasha Miller, Douglas H. Thamm
Publikováno v:
Veterinary and Comparative Oncology. 15:1564-1571
Background In humans geographical differences in the incidence and presentation of various cancers have been reported. However, much of this information has not been collected in veterinary oncology. Aim The purpose of this study was to determine if
Publikováno v:
Veterinary and Comparative Oncology. 13:314-321
Masitinib mesylate is a tyrosine kinase inhibitor approved for the treatment of gross, non-metastatic grade II and III canine mast cell tumours (MCTs). This study evaluated the use of masitinib as a frontline and rescue agent for metastatic and non-m
Autor:
J. C. Phillips, Quanhua Liu, Yun Seo Koo, Aly E. Fathy, L. M. Lembcke, O. A. Smrkovski, Robab Kazemi
Publikováno v:
Veterinary and Comparative Oncology. 11:14-29
Performance and clinical characteristics of a novel hyperthermia antenna operating at 434 MHz were evaluated for the adjuvant treatment of locally advanced superficial tumours in cats, dogs and horses. Electromagnetic simulations were performed to de
Publikováno v:
Veterinary and comparative oncology. 13(3)
Masitinib mesylate is a tyrosine kinase inhibitor approved for the treatment of gross, non-metastatic grade II and III canine mast cell tumours (MCTs). This study evaluated the use of masitinib as a frontline and rescue agent for metastatic and non-m